Mosekilde L, Jastrup B, Melsen F, Lund B, Lund B, Sørensen O H, Nielsen H E, Yde H
Eur J Clin Invest. 1984 Apr;14(2):96-102. doi: 10.1111/j.1365-2362.1984.tb02095.x.
The effect of propranolol 160-640 mg/day for 3 months on the accelerated loss of bone matrix and mineral in hyperthyroidism was studied in seventeen patients. A rise in serum thyroxine (P less than 0.01) during the first 3 weeks was followed by a fall (P less than 0.02). Serum triiodothyronine declined during the study (P less than 0.02). The enhanced bone mineral mobilization and collagen turnover continued during treatment and the bone mineral content decreased 3.2% (P less than 0.01). The secondary adaptive changes in serum parathyroid hormone and vitamin-D metabolites and in renal phosphate handling stayed unchanged. Iliac crest bone biopsies after tetracycline double-labelling showed initially a high bone turnover (P less than 0.01) with a reduced amount of cortical and trabecular bone (P less than 0.05). Following treatment bone formation rate decreased at both cellular and tissue level (P less than 0.01). No significant changes were observed in the amount of cortical and trabecular bone. The investigation shows that propranolol, in contrast to antithyroid medication, lacks any curative effect on the accelerated bone loss in hyperthyroidism.
对17例甲状腺功能亢进患者研究了每日服用160 - 640毫克普萘洛尔，持续3个月对加速的骨基质和矿物质流失的影响。在最初3周血清甲状腺素升高（P<0.01），随后下降（P<0.02）。在研究期间血清三碘甲状腺原氨酸下降（P<0.02）。在治疗期间，增强的骨矿物质动员和胶原蛋白周转持续存在，骨矿物质含量下降了3.2%（P<0.01）。血清甲状旁腺激素、维生素D代谢产物以及肾脏对磷酸盐处理的继发性适应性变化保持不变。四环素双重标记后的髂嵴骨活检最初显示骨转换率高（P<0.01），皮质骨和小梁骨量减少（P<0.05）。治疗后，细胞和组织水平的骨形成率均下降（P<0.01）。皮质骨和小梁骨量未观察到显著变化。该研究表明，与抗甲状腺药物相比，普萘洛尔对甲状腺功能亢进症中加速的骨质流失缺乏任何治疗效果。
